Vaccines for preventing herpes zoster in older adults

Gagliardi, Ana M. Z.; Silva, Brenda Nazaré Gomes; Torloni, Maria Regina; Soares, Bernardo Garcia de Oliveira

BACKGROUND:

Herpes zoster or, as it is commonly called, 'shingles' is a neurocutaneous disease characterised by the reactivation of varicella zoster virus (VZV), the virus that causes chickenpox, which is latent in the dorsal spinal ganglia when immunity to VZV declines. It is an extremely painful condition which can often last for many weeks or months, impairing the patient's quality of life. The natural aging process is associated with a reduction of cellular immunity which predisposes to herpes zoster. Vaccination with an attenuated form of VZV activates specific T cell production, therefore avoiding viral reactivation. A herpes zoster vaccine with an active virus has been approved for clinical use among older adults by the Food and Drug Administration and has been tested in large populations.

OBJECTIVE:

To evaluate the effectiveness and safety of vaccination for preventing herpes zoster in older adults. METHODS Search

methods:

We searched the following sources for relevant studies CENTRAL 2012, Issue 7, MEDLINE (1948 to July week 1, 2012), EMBASE (2010 to July 2012), LILACS (1982 to July 2012) and CINAHL (1981 to July 2012). We also reviewed reference lists of identified trials and reviews for additional studies. Selection criteria Randomised controlled trials (RCTs) or quasi-RCTs comparing zoster vaccine with placebo or no vaccine, to prevent herpes zoster in older adults (mean age > 60 years). Data collection and

analysis:

Two review authors independently collected and analysed data using a data extraction form. They also carried out an assessment of risk of bias. MAIN

RESULTS:

We identified eight RCTs with a total of 52,269 participants. Three studies were classified at low risk of bias. The main outcomes on effectiveness and safety were extracted from one clinical trial with a low risk of bias. Four studies compared zoster vaccine versus placebo; one study compared high-potency zoster vaccine versus low-potency ...

BVS IEC

Instituto Evandro Chagas

Formato de exportação: